Coro2A在非小细胞肺癌中的表达及临床相关研究

发布时间：2018-08-18 18:30

【摘要】：[目的]本研究拟通过观察Coro2A蛋白在非小细胞肺癌(non-small lung cancer, NSCLC)癌组织及癌旁正常肺组织的表达情况,探讨Coro2A蛋白与NSCLC患者临床病理特征的关联,为NSCLC分子靶向治疗提供实验依据。[方法]收集2008年1月至2016年1月昆明医科大学第三附属医院胸外科110例初治NSCLC患者经手术标本取材的癌组织和癌旁正常肺组织标本,并能获得完整的NSCLC患者临床病历资料。手术中切除的标本均由10%中性福尔马林溶液固定,后经脱水,包埋,染色后在显微镜下进行细胞形态学观察,应用HE染色和IHC染色技术,检测非小细胞肺癌癌组织和癌旁正常肺组织中Coro2A蛋白的表达情况。分析Coro2A蛋白的表达情况与NSCLC患者的临床病理特征的关系。结果采用SPSS20.0软件进行统计分析,P0.05为差异有统计学意义。[结果]1. Coro2A蛋白在非小细胞肺癌癌组织和癌旁正常肺组织的表达情况Coro2A蛋白主要表达于非小细胞肺癌癌组织和癌旁正常肺组织的细胞质和细胞核。在110例非小细胞肺癌癌组织中Coro2A蛋白阳性表达58例,阳性表达率为52.7%(58/110)：在癌旁正常肺组织中Coro2A蛋白阳性表达83例,阳性表达率为75.5%(83/110)。两者之间的Coro2A蛋白阳性表达率差异有统计学意义(P0.001),提示Coro2A蛋白在NSCLC癌组织的阳性表达率明显低于癌旁正常肺组织。2. Coro2A蛋白在不同性别非小细胞肺癌患者癌组织的表达情况在110例非小细胞肺癌癌组织中,Coro2A蛋白在男性NSCLC患者癌组织中阳性表达44例,阳性表达率为62.9%(44/70);Coro2A蛋白在女性NSCLC患者癌组织中阳性表达14例,阳性表达率为35%(14/40)。两者之间的Coro2A蛋白阳性表达率差异具有统计学意义(P0.05),提示Coro2A蛋白在男性非小细胞肺癌癌组织的阳性表达率高于女性。3. Coro2A蛋白在不同组织类型非小细胞肺癌癌组织的表达情况在110例非小细胞肺癌癌组织中,Coro2A蛋白在腺癌组织中阳性表达36例,阳性表达率为48.6%(36/74); Coro2A蛋白在鳞状细胞癌组织中阳性表22例,阳性表达率为61.1%(22/36)。两者阳性表达率差异无统计学意义(P0.05),提示Coro2A蛋白在非小细胞肺癌癌组织中的阳性表达率与组织类型无相关性。4. Coro2A蛋白在不同NSCLC患者临床病理参数的表达情况在110例非小细胞肺癌癌组织中,Coro2A蛋白在低年龄组(发病年龄≤60岁)的NSCLC患者癌组织中阳性表达33例,阳性表达率为60.0%(33/55),Coro2A蛋白在高年龄组(发病年龄60岁)的NSCLC患者癌组织中阳性表达25例,阳性表达率为45.6%(25/55)。两者之间的Coro2A蛋白阳性表达率差异无统计学意义(P0.05)。Coro2A蛋白在原发肿瘤情况为T1、T2及T3的NSCLC患者中阳性表达分别为28例、24例、6例,阳性表达率分别为53.8%(28/52)、54.5%(24/44)、42.9%(6/14)。三者之间的Coro2A蛋白阳性表达率差异无统计学意义(P0.05)；Coro2A蛋白在淋巴结转移情况为N0、N1/N2的NSCLC患者中阳性表达分别为27例、31例,阳性表达率分别为50.0%(27/54)、55.4%(31/56),两者之间的Coro2A蛋白阳性表达率差异无统计学意义(P0.05)；Coro2A蛋白在病理分期为Ⅰ期、Ⅱ期及Ⅲ期的NSCLC患者中阳性表达分别为23例、14例、21例,阳性表达率分别为56.1%(23/41)、51.9%(14/27)、50.0%(21/42),三者之间的Coro2A蛋白阳性表达率差异无统计学意义(P0.05)。上述结果提示Coro2A蛋白在非小细胞肺癌癌组织的阳性表达率与年龄、原发肿瘤情况、淋巴结转移情况及病理分期无相关性。[结论]1. Coro2A蛋白在NSCLC癌组织的阳性表达率低于癌旁肺组织,提示Coro2A可能在非小细胞肺癌起抑癌作用；2. Coro2A蛋白在男性NSCLC患者癌组织的阳性表达率高于女性,提示Coro2A可能与男性非小细胞肺癌的发生密切相关；3. Coro2A蛋白在NSCLC癌组织的阳性表达率与年龄、组织病理类型、原发肿瘤灶情况、淋巴结转移情况及病理分期无相关性。
[Abstract]:[Objective] To investigate the expression of Coro2A protein in non-small lung cancer (NSCLC) tissues and adjacent normal lung tissues, and to explore the relationship between Coro2A protein and clinicopathological characteristics of NSCLC patients, so as to provide experimental basis for molecular targeted therapy of NSCLC. [Methods] Kunming doctors from January 2008 to January 2016 were collected. The specimens were fixed by 10% neutral formalin solution, then dehydrated, embedded, stained and stained under a microscope. HE staining and IHC staining were used to detect the expression of Coro2A protein in non-small cell lung cancer tissues and adjacent normal lung tissues. Coro2A protein was mainly expressed in the cytoplasm and nucleus of non-small cell lung cancer tissues and adjacent normal lung tissues. Coro2A protein was positive in 58 of 110 non-small cell lung cancer tissues, with a positive expression rate of 52.7% (58/110): in adjacent cancer tissues. The positive expression rate of Coro2A protein was 75.5% (83/110) in 83 normal lung tissues. There was significant difference in the positive expression rate of Coro2A protein between the two groups (P 0.001), suggesting that the positive expression rate of Coro2A protein in NSCLC cancer tissues was significantly lower than that in adjacent normal lung tissues. The positive expression rate of Coro2A protein was 62.9% (44/70) in male NSCLC patients and 35% (14/40) in female NSCLC patients. The positive expression rate of Coro2A protein in male non-small cell lung cancer tissues was higher than that in female. 3. The expression of Coro2A protein in different tissue types of non-small cell lung cancer tissues in 110 non-small cell lung cancer tissues, the positive expression rate of Coro2A protein in adenocarcinoma tissues was 48.6% (3%). The positive expression rate of Coro2A protein was 61.1% (22/36) in 22 cases of squamous cell carcinoma. There was no significant difference between the positive expression rate of Coro2A protein and non-small cell lung cancer (P 0.05), suggesting that there was no correlation between the positive expression rate of Coro2A protein and tissue type. 4. Coro2A protein in different NSCLC patients with clinicopathological parameters. The expression of Coro2A protein was found in 33 cases of NSCLC in the younger age group (onset age < 60 years old), and in 25 cases of NSCLC in the older age group (onset age 60 years old), with a positive expression rate of 45.6% (25/55). There was no significant difference in the positive expression rate of Coro2A protein between the two groups (P 0.05). The positive expression rate of Coro2A protein in the patients with NSCLC of T1, T2 and T 3 was 53.8% (28/52), 54.5% (24/44) and 42.9% (6/14), respectively. The positive expression rate of Coro2A protein was 50.0% (27/54) and 55.4% (31/56), respectively, in NSCLC patients with N0 and N1/N2 lymph node metastasis (P 0.05). There was no significant difference in the positive expression rate of Coro2A protein between the two groups (P 0.05); Coro2A protein was found in stage I, stage II and stage III NSCLC patients. The positive expression rate of Coro2A protein was 56.1% (23/41), 51.9% (14/27) and 50.0% (21/42), respectively. There was no significant difference in the positive expression rate of Coro2A protein among the three groups (P 0.05). The positive expression of Coro2A protein in NSCLC tissues was lower than that in adjacent lung tissues, suggesting that Coro2A may play an inhibitory role in non-small cell lung cancer. 2. The positive expression of Coro2A protein in male NSCLC tissues was higher than that in female, suggesting that Coro2A may be associated with male non-small cell lung. The positive expression rate of Coro2A protein in NSCLC was not correlated with age, histopathological type, primary tumor, lymph node metastasis and pathological stage.
【学位授予单位】：昆明医科大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R734.2

【相似文献】